Cited by 739Biochemical and Molecular ResearchPI3K/AKT/mTOR signaling in cancerMetabolism, Diabetes, and Cancer

Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1

Open access
Ben-Sahra, Issam, Howell, Jessica J., Asara, John M., Manning, Brendan D.·2013·Science

Abstract

Coordinating Metabolism: Growth factors help to coordinate metabolism with growth in part by stimulating the activity of the protein kinase mTORC1 (mechanistic target of rapamycin complex 1). Ben-Sahra et al. (p. 1323 , published online 21 February) and Robitaille et al. (p. 1320 , published online 21 February) independently identified a key target of mTORC1—carbamolyl-phosphate synthase 2, or CAD, the rate-limiting enzyme for de novo synthesis of pyrimidines. Metabolomic profiling and phosphoproteomic analyses of normal cells and cells lacking signaling by mTORC1 converged on CAD as a key point at which growth-promoting signals also ramp up production of nucleic acids.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/science.1228792

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Activation of mTOR can increase ribose synthesis via the oxidative pentose phosphate pathway and enhance flux through pyrimidine and purine synthesis pathways.

    “Activation of mTOR can increase ribose synthesis via the oxidative pentose phosphate pathway (Duvel et al., 2010) and enhance flux through the pyrimidine and purine synthesis pathways (Ben-Sahra et al., 2013; Ben-Sahra et al., 2016; Robitaille et al., 2013), suggesting that targeting nucleotide metabolism in tumor contexts with mTOR hyperactivation may be more effective.”

    From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Ben-Sahra et al., 2013

  • Targeting nucleotide metabolism may be more effective in tumor contexts with mTOR hyperactivation.

    “Activation of mTOR can increase ribose synthesis via the oxidative pentose phosphate pathway (Duvel et al., 2010) and enhance flux through the pyrimidine and purine synthesis pathways (Ben-Sahra et al., 2013; Ben-Sahra et al., 2016; Robitaille et al., 2013), suggesting that targeting nucleotide metabolism in tumor contexts with mTOR hyperactivation may be more effective.”

    From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Ben-Sahra et al., 2013

  • Glutamine-induced activation of mTORC1 results in phosphorylation of CAD, which catalyzes the condensation reaction converting glutamine-derived nitrogen into the pyrimidine precursor orotate.

    “Moreover, glutamine-induced activation of mTORC1 results in the phosphorylation of the enzyme complex called carbamoyl phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD), which catalyzes the condensation reaction converting glutamine-derived nitrogen into the pyrimidine precursor orotate34,35.”

    From Glutamine reliance in cell metabolism (2020) · cites this paper as [34]

  • CAD activity is regulated via phosphorylation by MAPK and by mTORC1-dependent S6 kinase.

    “Furthermore, activity of CAD enzyme is regulated via phosphorylation by MAPK and by mTORC1-dependent S6 kinase (Ben-Sahra et al., 2013; Graves et al., 2000; Robitaille et al., 2013).”

    From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Ben-Sahra et al., 2013

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ben-Sahra, I., Howell, J. J., Asara, J. M., & Manning, B. D.
Affiliations
  • Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston, MA 02115, USA.
  • Harvard University (US)
  • Beth Israel Deaconess Medical Center (US)
Corresponding author
  • Howell, Jessica J.
  • Manning, Brendan D.
Venue
Science
Published
2013-03-15
Volume
339
Issue
6125
Pages
1323-1328
ISSN
  • 0036-8075 (ISSN-L)
  • 1095-9203
OpenAlex
W1982789056
Cited by
739
References
23
Citations by year
2026: 35 · 2025: 48 · 2024: 41 · 2023: 43 · 2022: 75 · 2021: 74 · 2020: 64 · 2019: 61 · 2018: 57 · 2017: 63 · 2016: 51 · 2015: 55 · 2014: 49 · 2013: 23
FWCI
26.56
Type
journal article
Language
en
Open access
Locations
  • Science (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Cancer Institute (R01CA122617, P01CA120964, P30CA006516)
  • National Institute of Diabetes and Digestive and Kidney Diseases (F32DK095508)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords
de novo pyrimidine biosynthesis, mTORC1, S6K1, growth signaling, anabolic metabolism, S6K, ribosome biogenesis, nucleotide synthesis, protein kinase signaling
MeSH terms
Mechanistic Target of Rapamycin Complex 1, Tuberous Sclerosis Complex 2 Protein, Animals, Aspartate Carbamoyltransferase, Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing), Dihydroorotase, HeLa Cells, Humans, Pyrimidines, Signal Transduction, Ribosomal Protein S6 Kinases, Tumor Suppressor Proteins, 3T3-L1 Cells, Multiprotein Complexes, Mice, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review